Inmode Ltd

Análisis de la acción Inmode Ltd (INMD)

$14.140

+0.071 (+0.50%)Al cierre

Loading chart…
Máximo
14.210
Apertura
14.140
Precio medio ponderado por volumen
14.15
Volumen
379.10K
Capitalización
1.53B
Mínimo
14.090
Importe
5.36M
EV/EBITDA, TTM
8.59

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

inmodemd.com

Análisis de IA of Inmode Ltd (INMD)

Mantener

InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.

Métricas de valoración

El PER previsto actual de Inmode Ltd (INMD) es 9.99, frente a su media de 5 años de 12.33.

PER previsto

Valor razonable
Media 5A P/E
12.33
P/E actual
9.99
Sobrevalorada
18.82
Infravalorada
5.85

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
8.52
EV/EBITDA actual
8.59
Sobrevalorada
13.84
Infravalorada
3.19

Precio/ventas previsto

Valor razonable
Media 5A P/S
4.48
P/S actual
2.15
Sobrevalorada
7.18
Infravalorada
1.77

Escenarios de precio de Alphio AI para INMD

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%INMD

$15.83

Precio del escenario

B

Base

Base · 50%INMD

$13.90

Precio del escenario

B

Bajista

Bajista · 25%INMD

$12.59

Precio del escenario

Ballenas con INMD en cartera

H

Harel Insurance Investments & Financial Services Ltd

+ Con en carteraINMD

+4.49%

Rentabilidad a 3 meses

M

Meitav Investment House Ltd

+ Con en carteraINMD

-2.39%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-19 (ET)

08:30:00

Steel Partners Proposes to Acquire InMode at $16.75 per Share

2026-10-13 (ET)

07:30:00

InMode Finalizing Q3 2026 Financial Results

2026-10-12 (ET)

09:00:00

Applix Inc. Borrow Rate Increases to 12.22%

2026-08-05 (ET)

08:00:00

Sees FY26 Revenue of $365M-$375M

2026-07-10 (ET)

07:30:00

InMode Receives Acquisition Proposal from Steel Partners

Noticias

Preguntas frecuentes sobre INMD, respondidas por Alphio AI

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar